Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review
- PMID: 35116543
- PMCID: PMC8798074
- DOI: 10.21037/tcr-20-3417
Serum amyloid A protein in cancer prognosis: a meta-analysis and systematic review
Abstract
Background: Published studies showed divergent results of the prognostic value of serum amyloid A protein (SAA) in patients with different cancers. Therefore, we conducted this meta-analysis so as to assess the association between SAA and cancer prognosis.
Methods: A comprehensive search was conducted to identify the literatures working over SAA and survival in patients with cancers published until January 2020. Sufficient data for assessing overall survival in cancers were extracted descriptively and quantitatively from the studies and a pooled odds ratio was calculated using the Mantel-Haenszel fixed-effect or random-effect model.
Results: Ten eligible papers were identified by two reviewers independently, including 4 studies that evaluated renal cell carcinoma (RCC), 2 studies evaluated lung cancer and the other 3 studies evaluated melanoma, gastric cancer and different cancers. Elevated SAA expression and shorter overall survival (OS) had a statistically significant relation [pooled 1-year OR was 5.07, 95% confidence interval (CI), 3.71-6.94, Q=9.15, I2=0%; pooled 3-year OR was 4.21, 95% CI, 3.18-5.56, Q=14.94, I2=46%; pooled 5-year OR was 5.69, 95% CI, 2.66-12.18, Q=24.83, I2=80%]. Subgroup analysis of RCC patients showed remarkable association between SAA and shorter OS (pooled 1-year OR =4.76, 95% CI, 3.00-7.56, Q=4.18, I2=4%; pooled 3-year OR =4.89, 95% CI, 3.06-7.81, Q=2.88, I2=0%).
Conclusions: High SAA status is correlated with an unfavorable OS in different cancers, especially in RCC, and digestive cancer.
Keywords: Serum amyloid A proteins (SAA); cancer; overall survival (OS); prognostic factor; tumor marker.
2021 Translational Cancer Research. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-3417). The authors have no conflicts of interest to declare.
Figures





Similar articles
-
The prognostic value of serum amyloid A in solid tumors: a meta-analysis.Cancer Cell Int. 2019 Mar 20;19:62. doi: 10.1186/s12935-019-0783-4. eCollection 2019. Cancer Cell Int. 2019. PMID: 30930691 Free PMC article. Review.
-
Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.BMC Urol. 2020 Jul 6;20(1):90. doi: 10.1186/s12894-020-00665-8. BMC Urol. 2020. PMID: 32631294 Free PMC article.
-
Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.Clin Chim Acta. 2018 May;480:166-172. doi: 10.1016/j.cca.2018.02.014. Epub 2018 Feb 17. Clin Chim Acta. 2018. PMID: 29462592
-
Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma.Dis Esophagus. 2014 Sep-Oct;27(7):670-7. doi: 10.1111/dote.12128. Epub 2013 Aug 30. Dis Esophagus. 2014. PMID: 24033446
-
C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.Clin Chim Acta. 2017 Dec;475:178-187. doi: 10.1016/j.cca.2017.10.021. Epub 2017 Nov 6. Clin Chim Acta. 2017. PMID: 29080691
Cited by
-
Serum amyloid alpha 1-2 are not required for liver inflammation in the 4T1 murine breast cancer model.Front Immunol. 2023 Feb 3;14:1097788. doi: 10.3389/fimmu.2023.1097788. eCollection 2023. Front Immunol. 2023. PMID: 36817472 Free PMC article.
-
Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance.J Mass Spectrom Adv Clin Lab. 2023 Nov 20;30:51-60. doi: 10.1016/j.jmsacl.2023.11.001. eCollection 2023 Nov. J Mass Spectrom Adv Clin Lab. 2023. PMID: 38074293 Free PMC article.
-
Recent Advances in Studies of Serum Amyloid A: Implications in Inflammation, Immunity and Tumor Metastasis.Int J Mol Sci. 2025 Jan 24;26(3):987. doi: 10.3390/ijms26030987. Int J Mol Sci. 2025. PMID: 39940756 Free PMC article. Review.
-
Plasma Proteomic Signature of Endometrial Cancer in Patients with Diabetes.ACS Omega. 2024 Jan 18;9(4):4721-4732. doi: 10.1021/acsomega.3c07992. eCollection 2024 Jan 30. ACS Omega. 2024. PMID: 38313512 Free PMC article.
-
Clinical performance evaluation of serum amyloid A module of Mindray BC-7500CS automated hematology analyzer.Transl Pediatr. 2023 Jan 31;12(1):20-30. doi: 10.21037/tp-22-661. Epub 2023 Jan 16. Transl Pediatr. 2023. PMID: 36798927 Free PMC article.
References
LinkOut - more resources
Full Text Sources